Paul Smith

Company: Recludix Pharma

Job title: Senior Vice President, Biology

Seminars:

Discovery of Potent & Selective Oral STAT3 Inhibitors with Potential Efficacy & Safety Differentiation Versus JAK/ TYK2 Targeting 2:00 pm

SH2 domain discovery platform integrating DNA-encoded libraries and crystallography enabled drug design Optimizing inflammatory cytokine inhibition to achieve deep and durable immune modulation Utilizing translational assays to explore infection and hematologic homeostasis differentiationRead more

day: Conference Day Two

Panel Discussion: Monoclonals, Topicals, Orals, Targets, Mild Disease & More – Where Are the Industry’s Priorities to Develop Safe Therapies with Superior Efficacy? 9:30 am

With a rich pipeline of drugs targeting various inflammatory mechanisms, for different indications and leveraging different approaches, what will be the next blockbuster drug to reach the market? How are safety concerns around systemics and efficacy challenges around topicals being addressed, amidst regulatory and reimbursement environments? Faced with varying challenges to demonstrating clinical superiority and…Read more

day: Conference Day One